-56%

est. 2Y upside i

HealthcareSeries B

Rank

#3730

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Low

Given an estimated entry valuation of $250M, revenue of $2.1M, and significant preference overhang of $120M, the probability-weighted expected upside over 2 years is -56%.

Last updated: July 3, 2026

Bull (10%)+12%

Exit multiple holds at 100x on pre-IPO momentum from KOSDAQ listing; projected revenue $3.3M yields exit value ~$330M. After 20% dilution, common sees 12% upside.

Base (55%)-41%

Exit multiple converges to 60x, exit value ~$198M. Preference overhang of $120M and 20% dilution lead to ~41% loss for common.

Bear (35%)-100%

Exit multiple compresses to 30x, exit value ~$99M below $120M liquidation preference; common stock recovers zero.

Est. time to liquidity~1.5 years

Preference Stack Risk

severe

Funding Intensity

4800%

Total funding of $120M represents 48% of assumed $250M valuation, creating a severe preference overhang that leaves common at risk of zero recovery in a down round.

Dilution Risk

high

With negative cash flow and only $2.1M revenue, another raise within 12-18 months is likely, implying 15-25% additional dilution for common holders.

Secondary Liquidity

none

No secondary market activity reported; shares are illiquid until an IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on GenEdit's data — designed to show you've done your homework.

  • 1

    “How does BreezeBio's NanoGalaxy platform achieve better tissue specificity than LNPs or AAVs, and what data supports that?”

  • 2

    “What is the revenue contribution from partnerships versus internal pipeline, and how do you expect that mix to evolve?”

  • 3

    “Given the preference stack, what is the projected fully diluted share count and what ownership percentage would this equity grant represent?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.